Cerenome (CNSY) is projected to report a third-quarter loss of $0.98 per share on revenue of $0.75 million, with the stock currently trading at $3.29 relative to a $37.00 average analyst target.
Investors are primarily focused on the commercial conversion of CNSide diagnostic gross billings into realized GAAP revenue for the Q3 2026 period.
While the company recently pre-announced $1.55 million in gross payer billings for the quarter, management indicated that initial cash collections are not anticipated to begin until the fourth quarter. Supporting the outlook, shareholders are also awaiting a final CMS Medicare pricing decision and updates on the company’s capital runway following recent financing agreements.